Printer Friendly

Five Years' Outcomes of Trabeculectomy with Cross-linked Sodium Hyaluronate Gel Implantation for Chinese Glaucoma Patients.

Byline: Xiao. Wang, Wan-Wei. Dai, Ya-Long. Dang, Ying. Hong, Chun. Zhang

Background: Trabeculectomy is the most efficient surgical treatment. Prevention failure of bleb cicatrix would lead to unsatisfactory postoperative intraocular pressure (IOP) controlling and unsatisfactory success rate. The aim of this study was to evaluate the 5-year outcomes of trabeculectomy with a cross-linked sodium hyaluronate gel implantation for Chinese glaucoma patients. Methods: This is a prospective, case-controlled study. Patients who were to be applied first-time trabeculectomy in the Department of Ophthalmology of Peking University Third Hospital between 2010 and 2012 were included in the study. Totally, 60 eyes were randomly assigned to the trabeculectomy group (TA group) or the trabeculectomy with cross-linked sodium hyaluronate gel implantation group (TH group). Follow-up was finished at 1 week, 1 month, 3 months, 1 year, 3 years, and 5 years after the operation. The statistical index of demographic data, IOP, bleb shape, and any complications or medications or surgical procedures were recorded and assessed by SPSS 19.0 software through independent t-test, one-way analysis of variance (ANOVA) and Pearson's Chi-square test, respectively. Results: The baseline IOP was comparable between the two groups (t= −1.00, P= 0.32) while the postoperative IOP was significantly lower in the TH group at 1, 3 and 5 years' time points (P = 0.00, P= 0.01 and P = 0.01, respectively). According to the Indiana Bleb Appearance Grading Scale, the height and extent of bleb were better in the TH group at all follow-up time points (P < 0.05), however, the comparison of bleb vascularity showed no statistical difference (P > 0.05). TA group had a higher percentage of complications (13% vs. 3%) compared to TH group; however, there was no statistical difference in the comparison of each statistical item (P > 0.05, respectively). The complete success at 5 years was higher in the TH group than that in the TA group (78% vs. 54%, P = 0.03). Conclusion: Our results suggested that implantation of cross-linked sodium hyaluronate gel with trabeculectomy was more efficient and would improve the prognosis of glaucoma patients.


Glaucoma is characterized by progressive optic nerve damage and visual field defect.[1] Vision loss in glaucoma resulting from retinal ganglion cell death is triggered by orbital cerebrospinal fluid pressure.[2] Even though neuroprotection strategy has been developed,[3],[4] lowering intraocular pressure (IOP) is currently the most effective way to prevent the progression of glaucomatous optic neuropathy. A previous study showed that each mmHg (1 mmHg = 0.133 kPa) of IOP reduction would decrease the risk of optic nerve damage by approximately 10%.[5]

IOP management for glaucoma patients includes anti-glaucoma medication, laser therapy, needling procedures, and filtering surgery (or tube shunt implantation). Till now, trabeculectomy is still the most efficient option for those with progressive glaucoma.[6] Cicatrix is the major cause of postoperative bleb failure and significantly affects the long-term success rate of trabeculectomy.[7],[8],[9],[10] The use of antimitotic agents such as 5-fluorouracil and mitomycin C (MMC) has been widely accepted as the golden standard of trabeculectomy, apparently reducing the incidence of scar formation and enhancing bleb surviving rate. However, the postoperative scarring process of filtering bleb would always get worse and affect long-term success rate.[11] Moreover, they have many terrible complications with high incidence rate, such as infection, thin-walled bleb, irregular edema of epithelium, and toxic effects to eyes.[12] Bleb leakage would also exert bad influence on normal filtering function. Those possible side effects which could not be easily cured radically and prevented would finally affect postoperative visual function and success rate. Those antimitotic agents' complications are unignorable and the dosage and local action time are to be controlled strictly during surgery. However, some other medical materials such as sodium hyaluronate are nonimmunogenicity, and intraoperative implantation would not be restricted by local action time strictly. Therefore, rich experience in antimitotic drug usage of ophthalmologist and prudent attitude are in great need which would increase difficulties in surgical technique learning. As a result, developing more efficient anti-scarring method for trabeculectomy has always been a clinical need.

Previous studies have shown that cross-linked sodium hyaluronate gel may have antifibrotic effects in trabeculectomy.[13],[14],[15],[16] Other studies have also suggested that intraoperative implantation of sodium hyaluronate gel may prevent bleb scarring, fibrosis, adhesion and improve IOP.[17],[18],[19],[20] However, limited randomized and case-controlled studies have been conducted to investigate the long-term outcomes of cross-linked sodium hyaluronate gel applied in trabeculectomy in patients with glaucoma.


Ethical approval

This was a prospective, case-controlled study which had been approved by the Medical Ethics Committee of Peking University Third Hospital (No. 09-70, Nimo10-01-13) in compliance with the Declaration of Helsinki. All participants were informed of the whole surgical procedure and signed informed consent.


Glaucoma patients without prior intraocular surgeries were included and neovascular glaucoma were excluded from the study. All patients were enrolled at the Department of Ophthalmology of Peking University Third Hospital between 2010 and 2012. The patients were randomly assigned to the traditional trabeculectomy group (TA group) and the trabeculectomy with cross-linked hyaluronate gel implantation group (TH group). Random grouping number table was used as simple randomization.

Trabeculectomy with cross-linked sodium hyaluronate implantation

Standard trabeculectomy was performed as previously described.[21],[22] In brief, we made fornix-based conjunctival flap at 12 o'clock and a half-thickness sclera flap in 2 mm x 3 mm and then removed 1 mm x 2 mm corneal-sclera tissues and performed iridectomy. The scleral incision was sutured finally. For the TH group, 0.02 ml and 0.1 ml of 2.25% cross-linked sodium hyaluronate gel (HealaFlow, Anteis SA, Geneva, Switzerland) were injected under the scleral flap and the conjunctiva respectively before the closure of incisions. For the TA group, only standard trabeculectomy procedure was performed.

Outcome evaluations

All the patients were followed up at 1-week, 1-month, 3-month, 1-year, 3-year, and 5-year postoperation. IOP, bleb shape, and best-corrected visual acuity were observed. Any complication or add-on remedial anti-glaucoma medications or procedures were recorded. The primary measurement objective was the IOP reduction. The secondary outcomes included reduction of glaucoma medication, bleb formation change, and surgical complications. Bleb formation was evaluated by Indiana Bleb Appearance Grading Scale (IBAGS).[23]

Statistical analysis

Statistics were performed by SPSS 19.0 software (SPSS Inc. Chicago, IL, USA). Independent t -test and one-way analysis of variance (ANOVA) were used to evaluate the IOPs and numbers of glaucoma medication between the TH group and the TA group. Pearson's Chi-square test was used for demographic data.

The complete success was defined as IOP lower than 21 mmHg with no remedial glaucoma medication. Meanwhile, the qualified success was defined as IOP lower than 21 mmHg with glaucoma medication. Secondary glaucoma surgery was not included in the success rate investigation. Kaplan-Meier survival analysis was performed to calculate the 5-year success rate. All quantitative data were presented as mean [+ or -] standard deviation (SD). A P < 0.05 was considered statistically significant.



A total of 60 cases were enrolled in this study, of which 30 cases in the TH group and 30 cases in the TA group accomplished the 5-year follow-up. The age, gender, and diagnosis between the two groups showed no statistical difference (all P > 0.05). About 90% of the patients in TA group and 83% of the patients in TH group were primary glaucoma [Table 1]. The number of cases of each follow-up time point in the TA group was 30, 29, 27, 27, 22, and 19 and that of the TH group was 30, 30, 29, 26, 23, and 21, respectively. The percentage of loss to follow-up was 33% (20 cases). The comparison of loss to follow-up between the two groups at each time point showed no statistical difference ( P > 0.05). Fifteen cases (75%) of the 20 loss cases were for the reason of inconvenience of nonlocal residence. Reasons of loss to follow-up of another five cases were as follows: one bone fracture, one out of touch, one receiving heart stent, and two deaths.{Table 1}

Intraocular pressure

The preoperative IOP in the TH group was comparable to that of the TA group (30.60 [+ or -] 7.31 mmHg vs. 32.56 [+ or -] 7.80 mmHg, t = −1.00, P = 0.32). Both groups experienced dramatic IOP reductions at all follow-up time points (all P < 0.05, compared to each baseline). However, the IOPs in the TH group were significantly lower than that of the TA group at the 1, 3, and 5 years ( t = −3.46, P = 0.00; t = −2.72, P = 0.01; t = −2.58, P = 0.01) [Figure 1]a.{Figure 1}


The baseline numbers of glaucoma medication between the two groups showed no statistically different (0.57 [+ or -] 1.04 in the TH group vs. 0.43 [+ or -] 0.94 in the TA group, P = 0.93). However, the patients in the TH group had significantly less medication usage at the 3 and 5 years' time points, compared to the TA group ( P = 0.01 and P = 0.02, respectively) [Figure 1]b.

Bleb formation

The bleb formation was evaluated by one glaucoma specialist who used IBAGS.[23] The grading of bleb height and bleb extent in the TH group were significantly better at the 1, 3, and 5 years' time points (all P < 0.05) while the bleb vascularization was similar in comparison with the TA group ( P > 0.05).

Success rate investigation

The TH group had a higher complete success rate than the TA group. About 78% of patients in the TH group had postoperative IOP below 21 mmHg without glaucoma medication or secondary glaucoma surgery. Meanwhile, 54% of the TA group reached that goal at 5 years' time point ( P = 0.03) [Figure 2]a. However, the qualified success rate showed no statistical difference between TH and TA group (93% vs. 84%, P = 0.23) [Figure 2]b.{Figure 2}

Complications and secondary glaucoma surgery

The statistics of surgical complications and secondary glaucoma surgery were summarized as well [Table 2]. A few complications were observed in both groups, and the TA group had higher percentage (13% vs. 3%); however, there was no statistical difference in the comparison of each statistical item of postoperative complications (all P > 0.05). All complications were treated timely and effectively. No vision-threatening complication was encountered. Eight patients in the TA group required a bleb revision ( n = 5) or a secondary glaucoma surgery ( n = 3; two trabeculectomy and one transscleral cyclophotocoagulation). In contrast, only three patients in the TH group had remedial operations (two bleb revisions and one trabeculectomy).{Table 2}


Cross-linked sodium hyaluronate gel is a non-animal origin, biodegradable sodium hyaluronate which has an excellent feature of anti-inflammation, anti-fibrosis without cytotoxicity. It was initially used for rheumatoid arthritis patients accompanied by knee osteoarthritis.[24],[25] Recent studies suggested that the injection of cross-linked sodium hyaluronate gel under scleral flap and conjunctiva could inhibit the process of local fibrosis and vascularization and reduce the possibility of bleb failure, maintaining an effective filtration, and improving the long-term success rate of penetrating and nonpenetrating glaucoma surgeries.[15],[20],[26],[27] In this prospective study, we compared the safety and efficiency of trabeculectomy with cross-linked sodium hyaluronate gel injection for Chinese glaucoma patients and followed up for 5 years. Our data indicated that both trabeculectomy alone and trabeculectomy with cross-linked sodium hyaluronate gel injection group witnessed efficient lowering of IOP, while the patients in the cross-linked sodium hyaluronate gel injection group achieved more IOP reduction at 1, 3, and 5 years after operation. In addition, the patients with cross-linked sodium hyaluronate gel injection had a better bleb formation and less consumption of glaucoma medications and higher 5-year success rate and fewer surgical complications, suggesting that trabeculectomy with cross-linked sodium hyaluronate gel injection is better than trabeculectomy alone. Our results suggested that implantation of cross-linked sodium hyaluronate gel with trabeculectomy is an efficient and a safe option for Chinese glaucoma patients which would improve postoperative prognosis.

As a kind of sodium hyaluronate gel, cross-linked sodium hyaluronate gel might benefit the outcomes of trabeculectomy from its anti-inflammatory effect. In an experimental dry eye model, 0.18% of sodium hyaluronate eye drop remarkably inhibited the interferon-a induced release of inflammatory factors, such as tumor necrosis factor-alpha, interleukin (IL)-1beta, and reduced the percentages of CD4(+) CXCR3(+) cells in the conjunctiva.[28] In a double-blind and randomized clinical trial, Aragona et al .[29] also reported that sodium hyaluronate artificial tears reduced the ocular surface damage in patients with dry eye. Sodium hyaluronate also exhibited promising anti-inflammatory effects for the treatment of other diseases, especially for arthritis.[30],[31] However, sodium hyaluronate with different molecular weight showed apparent heterogeneities in biological functions such as inflammation. In an in vitro study, Albano et al .[32] found that only high molecular weight form of sodium hyaluronate efficiently inhibited the IL-17A-mediated activation of ERK1/2 and nuclear factor kappa B and production of reactive oxygen species in human nasal epithelial cells. In vivo , Mihara et al .[33] suggested that high molecular weight of sodium hyaluronate had a better effect on the progression of cartilage degeneration in a rabbit model of knee osteoarthritis, compared to nonsteroidal anti-inflammatory drug. In contrast, low molecular weight of sodium hyaluronate seemed to be a potent stimulus for inflammation and scarring.[34] Notably, the molecular structure of sodium hyaluronate may also affect its biological properties. Cross-linked sodium hyaluronate was more stable in structure characteristic, thus having a longer biodegradation time than the noncross-linked product. Moreover, cross-linked and noncross-linked sodium hyaluronate also showed different effects on proliferation of fibroblast [35] and skin barrier function.[36]

Our data showed that both trabeculectomy alone and trabeculectomy combined with cross-linked sodium hyaluronate gel implantation were efficient to lower IOP. This result was consistent with but a bit different from a previous study by Papaconstantinou et al .[15] In their study, they failed to identify a higher IOP reduction by injection of cross-linked sodium hyaluronate gel in comparison with trabeculectomy alone while we did found more IOP reduction in cross-linked sodium hyaluronate gel injection group at 1, 3, and 5 years' points after following up. Besides trabeculectomy, cross-linked sodium hyaluronate gel injection was also effective in nonpenetrating glaucoma surgery.[20] Bettin et al .[20] reported that the POAG patients achieved an incredibly high success rates (89-92%) at 36 months after receiving deep sclerectomy with MMC and cross-linked sodium hyaluronate gel.

In addition to anti-inflammatory effect, cross-linked sodium hyaluronate gel may inhibit the postoperative fibrosis and scar formation by its space-occupying property through mechanically separating the subconjunctival and episcleral tissues. A similar product using a biodegradable collagen stent (Ologen [R]) had been developed and the implantation of this collagen device during trabeculectomy had a better IOP reduction than using MMC.[37],[38],[39] The reduction in glaucoma medication and surgical complication showed no statistical difference. Although no study was available to compare the efficiency and safety of these two implantable devices for glaucoma surgery, the satisfying IOP outcomes provided possibility for further research on those medial materials.

MMC is an antimitotic agent widely used in trabeculectomy, inhibiting the postoperative fibrosis. Bleb leak was the most common complication,[37],[38],[39],[40],[41],[42] followed by aqueous misdirection, corneal abrasion, and Tenon's cyst formation. Choroidal detachment, choroidal hemorrhage, and endophthalmitis were occasionally reported, but vision-threatening complication had ever been reported.[13],[24] Bindlish et al. [40] reported the 5-year retrospective study outcomes of trabeculectomy with MMC among 123 glaucoma patients. Six months after surgery, 42.3% of participants had ocular hypotony. About 14.6% participants had severe complications of bleb leakage, and 8.9% participants had secondary surgery at the 2-year time point. By contrast, 3.3% participants in this study had secondary trabeculectomy, and the incidence rate of ocular hypotony and bleb leakage was lower than their study. Although our 5-year outcomes showed no statistical difference in single comparison of each postoperative side effect, the total amounts of the study group were fewer than the control group and bleb leakage times were fewer as well. Our results suggested that the implantation procedure had not enhanced the risk of occurrence of postoperative complications regarding the relatively low injection dosage and total sample size. The implantation of cross-linked sodium hyaluronate gel with trabeculectomy appeared to have a relatively safe profile. Although Rajiv Bindlish's study acquired higher 5th year success rate than our study (83% vs. 78%), our postoperative statistics of safety investigation were better, indicating that the relatively high safety of implantation was fit for surgical treatment.

There were several limitations for this study. First, due to the small sample size, it might not be able to detect the accurate differences in the incidence of complication and qualified success rate between the two groups. Second, 15 of 20 participants who lost from the follow-up are non-local residents. We knew that it was inevitable to have a certain portion of losing subjects for long-term follow-up trials. Among the 19 participants in the TA group two participants were nonlocal residents and others, and all participants in the TH group lived in the same city. We then did further investigation of the 5th year's follow-up between the two groups. Independent t -test results showed that mean IOP of the two groups were still standard normal distribution. IOP in the TH group was significantly lower than that of the TA group. The bleb height in the TH group was better while the bleb extent showed no significant difference. Vascularization level was similar in comparison with the TA group. So that we believed the lost rate did not affect the final success rate in our study. Third, an in vivo study using a rabbit model suggested that UV-cross-linked hyaluronate gel could be used as a vehicle to deliver and controlled-release tranilast for up to 26 h, facilitating the long-term success of IOP maintenance.[13] Futuristic studies using hyaluronate gel of different cross-linking rate implanted in trabeculectomy are expected.

In conclusion, our results suggested that implantation of cross-linked sodium hyaluronate gel with trabeculectomy appeared to be an efficient and safe option for glaucoma patients and could improve the prognosis of patients with glaucoma.

Financial support and sponsorship

This study was supported by the grants from the National Science Foundation of China (No. 81670851), the Natural Science Foundation of Beijing (No. 7172231), and the Capital Public Health Project of Beijing (No. Z151100003915143).

Conflicts of interest

There are no conflicts of interest.


1. Li BB, Cai Y, Pan YZ, Li M, Qiao RH, Fang Y, et al. Corneal biomechanical parameters and asymmetric visual field damage in patients with untreated normal tension glaucoma. Chin Med J 2017;130:334-9. doi: 10.4103/0366-6999.198920.

2. Jonas JB, Yang D, Wang N. Intracranial pressure and glaucoma. J Glaucoma 2013;22 Suppl 5:S13-4. doi: 10.1097/IJG.0b013e31829349bf.

3. Dang Y, Mu Y, Wang K, Xu K, Yang J, Zhu Y, et al. Papaverine inhibits lipopolysaccharide-induced microglial activation by suppressing NF-?B signaling pathway. Drug Des Devel Ther 2016;10:851-9. doi: 10.2147/DDDT.S97380.

4. Song W, Huang P, Zhang C. Neuroprotective therapies for glaucoma. Drug Des Devel Ther 2015;9:1469-79. doi: 10.2147/DDDT.S80594.

5. Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B; BESs Study Group. Risk factors for incident open-angle glaucoma: The Barbados Eye Studies. Ophthalmology 2008;115:85-93. doi: 10.1016/j.ophtha.2007.03.017.

6. Caprioli J, de Leon JM, Azarbod P, Chen A, Morales E, Nouri-Mahdavi K, et al. Trabeculectomy can improve long-term visual function in glaucoma. Ophthalmology 2016;123:117-28. doi: 10.1016/j.ophtha.2015.09.027.

7. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983;101:795-8. doi: 10.1001/archopht.1983.01040010795021.

8. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc U K 1983;103(Pt 1):84-8.

9. Jay JL. Rational choice of therapy in primary open angle glaucoma. Eye (Lond) 1992;6(Pt 3):243-7. doi: 10.1038/eye.1992.47.

10. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994;101:1651-6. doi: 10.1016/S0161-6420(94)31120-1.

11. Na JH, Sung KR, Shin JA, Moon JI. Antifibrotic effects of pirfenidone on Tenon's fibroblasts in glaucomatous eyes: Comparison with mitomycin C and 5-fluorouracil. Graefes Arch Clin Exp Ophthalmol 2015;253:1537-45. doi: 10.1007/s00417-015-3068-1.

12. Giampani J Jr., Borges-Giampani AS, Carani JC, Oltrogge EW, Susanna R Jr. Efficacy and safety of trabeculectomy with mitomycin C for childhood glaucoma: A study of results with long-term follow-up. Clinics (Sao Paulo) 2008;63:421-6.

13. Spitzer MS, Sat M, Schramm C, Schnichels S, Schultheiss M, Yoeruek E, et al. Biocompatibility and antifibrotic effect of UV-cross-linked hyaluronate as a release-system for tranilast after trabeculectomy in a rabbit model - A pilot study. Curr Eye Res 2012;37:463-70. doi: 10.3109/02713683.2012.658593.

14. Russo V, Scott IU, Stella A, Balducci F, Cosma A, Barone A, et al . Nonpenetrating deep sclerectomy with reticulated hyaluronic acid implant versus punch trabeculectomy: a prospective clinical trial. Eur J Ophthalmol 2008;18:751-7.

15. Papaconstantinou D, Diagourtas A, Petrou P, Rouvas A, Vergados A, Koutsandrea C, et al. Trabeculectomy with healaflow versus trabeculectomy for the treatment of glaucoma: A case-control study. J Ophthalmol 2015;2015:836269. doi: 10.1155/2015/836269.

16. Shoji N, Shimizu K, Takahashi K, Nemoto R, Kawai H, Tomioka T, et al . The application of cross-linked hyaluronate hydrogel to trabeculectomy. Nippon Ganka Gakkai Zasshi 2004;108:277-82.

17. Lopes JF, Moster MR, Wilson RP, Altangerel U, Alvim HS, Tong MG, et al. Subconjunctival sodium hyaluronate 2.3% in trabeculectomy: A prospective randomized clinical trial. Ophthalmology 2006;113:756-60. doi: 10.1016/j.ophtha.2006.01.040.

18. Sturmer J, Mermoud A, Sunaric Megevand G. Trabeculectomy with mitomycin C supplemented with cross-linking hyaluronic acid: A pilot study. Klin Monbl Augenheilkd 2010;227:273-6. doi: 10.1055/s-0029-1245186.

19. Roy S, Thi HD, Feusier M, Mermoud A. Crosslinked sodium hyaluronate implant in deep sclerectomy for the surgical treatment of glaucoma. Eur J Ophthalmol 2012;22:70-6. doi: 10.5301/ejo.5000054.

20. Bettin P, Di Matteo F, Rabiolo A, Fiori M, Ciampi C, Bandello F, et al. Deep sclerectomy with mitomycin C and injectable cross-linked hyaluronic acid implant: Long-term results. J Glaucoma 2016;25:e625-9. doi: 10.1097/IJG.0000000000000309.

21. Schlenker MB, Gulamhusein H, Conrad-Hengerer I, Somers A, Lenzhofer M, Stalmans I, et al. Efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy. Ophthalmology 2017;124:1579-88. doi: 10.1016/j.ophtha.2017.05.004.

22. Tseng VL, Kim CH, Romero PT, Yu F, Robertson-Brown KW, Phung L, et al. Risk factors and long-term outcomes in patients with low intraocular pressure after trabeculectomy. Ophthalmology 2017;124:1457-65. doi: 10.1016/j.ophtha.2017.05.014.

23. Cantor LB, Mantravadi A, WuDunn D, Swamynathan K, Cortes A. Morphologic classification of filtering blebs after glaucoma filtration surgery: The Indiana Bleb Appearance Grading Scale. J Glaucoma 2003;12:266-71. doi: 10.1097/00061198-200306000-00015.

24. Chou CL, Li HW, Lee SH, Tsai KL, Ling HY. Effect of intra-articular injection of hyaluronic acid in rheumatoid arthritis patients with knee osteoarthritis. J Chin Med Assoc 2008;71:411-5. doi: 10.1016/S1726-4901(08)70092-3.

25. Egelius N, Jonsson E, Sunblad L. Studies of hyaluronic acid in rheumatoid arthritis. Ann Rheum Dis 1956;15:357-63. doi: 10.1136/ard.15.4.357.

26. Mohamed MH, Abdelshafik MA, El Ibiary HM, Mohammed TH. Evaluation of the efficacy and safety of injectable cross-linked hyaluronic acid compared with mitomycin C in trabeculectomy surgery. J Egypt Ophthalmological Soc 2015;108:173. doi: 10.4103/2090-0686.174654.

27. Roy S, Thi HD, Feusier M, Mermoud A. Crosslinked sodium hyaluronate implant in deep sclerectomy for the surgical treatment of glaucoma. Eur J Ophthalmol 2012;22:70-6. doi: 10.5301/ejo.5000054.

28. Oh HJ, Li Z, Park SH, Yoon KC. Effect of hypotonic 0.18% sodium hyaluronate eyedrops on inflammation of the ocular surface in experimental dry eye. J Ocul Pharmacol Ther 2014;30:533-42. doi: 10.1089/jop.2013.0050.

29. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002;86:181-4. doi: 10.1136/bjo.86.2.181.

30. Masuko K, Murata M, Yudoh K, Kato T, Nakamura H. Anti-inflammatory effects of hyaluronan in arthritis therapy: Not just for viscosity. Int J Gen Med 2009;2:77-81. doi: 10.2147/IJGM.S5495.

31. Triantaffilidou K, Venetis G, Bika O. Efficacy of hyaluronic acid injections in patients with osteoarthritis of the temporomandibular joint. A comparative study. J Craniofac Surg 2013;24:2006-9. doi: 10.1097/SCS.0b013e3182a30566.

32. Albano GD, Bonanno A, Cavalieri L, Ingrassia E, Di Sano C, Siena L, et al. Effect of high, medium, and low molecular weight hyaluronan on inflammation and oxidative stress in an in vitro model of human nasal epithelial cells. Mediators Inflamm 2016;2016:8727289. doi: 10.1155/2016/8727289.

33. Mihara M, Higo S, Uchiyama Y, Tanabe K, Saito K. Different effects of high molecular weight sodium hyaluronate and NSAID on the progression of the cartilage degeneration in rabbit OA model. Osteoarthritis Cartilage 2007;15:543-9. doi: 10.1016/j.joca.2006.11.001.

34. Gulkilik G, Kocabora S, Engin G, Taskapili M, Yilmazli C, Kucuksahin H, et al . Sodium hyaluronate in trabeculectomy: Effect on early complications. Clin Exp Ophthalmol 2006;34:421-4.

35. Wohlrab J, Wohlrab D, Neubert RH. Comparison of noncross-linked and cross-linked hyaluronic acid with regard to efficacy of the proliferative activity of cutaneous fibroblasts and keratinocytes in vitro . J Cosmet Dermatol 2013;12:36-40. doi: 10.1111/jocd.12024.

36. Sundaram H, Mackiewicz N, Burton E, Peno-Mazzarino L, Lati E, Meunier S, et al . Pilot comparative study of the topical action of a novel, crosslinked resilient hyaluronic acid on skin hydration and barrier function in a dynamic, three-dimensional human explant model. J Drugs Dermatol 2016;15:434-41.

37. Senthil S, Rao HL, Babu JG, Mandal AK, Garudadri CS. Comparison of outcomes of trabeculectomy with mitomycin C vs. ologen implant in primary glaucoma. Indian J Ophthalmol 2013;61:338-42. doi: 10.4103/0301-4738.109520.

38. Cillino S, Casuccio A, Di Pace F, Cagini C, Ferraro LL, Cillino G, et al. Biodegradable collagen matrix implant versus mitomycin-C in trabeculectomy: Five-year follow-up. BMC Ophthalmol 2016;16:24. doi: 10.1186/s12886-016-0198-0.

39. He M, Wang W, Zhang X, Huang W. Ologen implant versus mitomycin C for trabeculectomy: A systematic review and meta-analysis. PLoS One 2014;9:e85782. doi: 10.1371/journal.pone.0085782.

40. Bindlish R, Condon GP, Schlosser JD, D'Antonio J, Lauer KB, Lehrer R, et al. Efficacy and safety of mitomycin-C in primary trabeculectomy: Five-year follow-up. Ophthalmology 2002;109:1336-41. doi: 10.1016/S0161-6420(02)01069-2.

41. Khairy HA1, Elsawy MF. Trabeculectomy With Mitomycin-C Versus Trabeculectomy With Amniotic Membrane Transplant: A Medium-term Randomized, Controlled Trial. J Glaucoma 2015;24:556-9. doi: 10.1097/IJG.0000000000000060.

42. Sarker BK, Abdullahi SM, Hassan Z, Kabir J, Badmus S, Alam S, Rahman M, et al . Outcome of trabeculectomy with Ologen versus Mitomycin C: A comparative prospective study in Bangladesh. Eur J Ophthalmol 2018 Apr 1:1120672118771841. [Epub ahead of print]. doi: 10.1177/1120672118771841.
COPYRIGHT 2018 Medknow Publications and Media Pvt. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original Article
Author:Wang, Xiao; Dai, Wan-Wei; Dang, Ya-Long; Hong, Ying; Zhang, Chun
Publication:Chinese Medical Journal
Article Type:Report
Geographic Code:9CHIN
Date:Jul 5, 2018
Previous Article:Comparison of Vaginal Gel and Intramuscular Progesterone for In vitro Fertilization and Embryo Transfer with Gonadotropin-Releasing Hormone...
Next Article:A Novel Mutation of Mitochondrial T14709C Causes Myoclonic Epilepsy with Ragged Red Fibers Syndrome in a Chinese Patient.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |